Author:
V.V. ZAKHAROV, N.V. VAKHNINA
Federal State Autonomous Educational Institution of Higher Education “First Moscow State Medical University named after I.M. Sechenov” of the Ministry of Health of the Russian Federation (Sechenov University), Moscow, Russia
Place of publication:
S.S. KORSAKOV JOURNAL OF NEUROLOGY AND PSYCHIATRY, 2024, Vol. 124, No. 1
Abstract:
The aim of the study was to conduct a meta-analysis of the effectiveness of Mexidol therapy in patients with chronic cerebral ischemia (CCI) and mild (moderate) cognitive impairment (CI).
Material and methods. This meta-analysis included the results of studies on the efficacy of Mexidol in CR, the severity of which was assessed using the MoCA scale. The pooled effect assessment included all publications on the results of independent clinical trials that provided efficacy assessment data using the MoCA scale at a level sufficient for further statistical analysis. The primary outcome of the meta-analysis was obtained for the final efficacy indicator values in the groups of patients receiving Mexidol compared to the background therapy groups.
Results. The meta-analysis included the results of 10 prospective clinical trials of the efficacy of Mexidol in combination with background therapy in patients with CCI and mild (moderate) CR. The main group consisted of 482 patients, the comparison group – 455. Using the random effects statistical model, the effect size was 2.06 points, 95% CI for the difference in efficacy in the two groups – [0.98; 3.14 points] (p=0.0002).
Conclusion. A statistically significant improvement in cognitive function in patients with chronic cerebral ischemia was demonstrated with the use of Mexidol.
Key words: chronic cerebral ischemia, cognitive impairment, ethylmethylhydroxypyridine succinate, Mexidol, treatment.